About
Johanna Mercier is Gilead's Chief Commercial and Corporate Affairs Officer, responsible for driving top-line revenue growth and expanding access to Gilead's therapies across virology, oncology and inflammation. In late 2025 she took on additional responsibility for the company's public affairs and government affairs functions worldwide.
She has been central to Gilead's portfolio diversification and led the launch of a novel long-acting option for HIV prevention as well as the rapid launch and global access efforts for Gilead's COVID-19 antiviral during the pandemic. Before joining Gilead in 2019, Ms. Mercier spent 25 years at Bristol Myers Squibb in senior leadership roles across the U.S. and international markets.
Roles
Gilead Sciences, Inc.
Chief Commercial and Corporate Affairs Officer · Current role
2019–present
Bristol Myers Squibb
Senior leadership roles across U.S. and international markets · Spent 25 years at Bristol Myers Squibb before joining Gilead.
—
Bristol Myers Squibb
President and Head, Large Markets division · Large Markets division included the United States, France, Germany and Japan; most recent BMS role before joining Gilead.
—
External Roles
Arcus Biosciences
Member, Board of Directors
—
Neurocrine Biosciences
Member, Board of Directors
—
USC Leonard D. Schaeffer Center for Health Policy and Economics
Board Member
—
Fixed Compensation
FY 2025
All other compensation
$102,980
Total compensation
$9,300,643
Performance Compensation
Data from FY 2025
Cash incentive
Annual cash incentive
$2,150,901
Stock awards
Also at Gilead Sciences, Inc.